Abstract:BACKGROUND & OBJECTIVE:Angiogenesis plays an important role in growth and metastasis of tumors. Vascular endothelial growth factor (VEGF) is considered as a fundamental regulator for angiogenesis. This study was to construct a recombinant T7 phage vaccine expressing xenogenic VEGF on the capsid, and test its inhibitory effect on Lewis lung cancer cells in mice.METHODS:VEGF gene was cloned by reverse transcription-polymerase chain reaction (RT-PCR) from human lung cancer tissues, and inserted into phage using T7 Select10-3b kit to construct T7 Select10-3b_VEGF vaccine. The titer of prepared phage reached 1x10(13) pfu/ml. C57BL/6J mice were randomly divided into 3 groups: T7 Select10-3b_VEGF vaccine group (T7-VEGF), T7 phage (T7) group, normal saline (NS) group (10 mice/group). Each mouse was injected with Freundos adjuvant mixed with 1x10(12) pfu/200 microl T7 Select10-3b_VEGF, or T7, or normal saline once a week for 4 weeks. Lewis lung carcinoma model (LL/2) was established in C57BL/6J mice after 4-week immunization. Tumor growth and mouse's physical status were observed during immunization. Tumor weight and serum level of specific anti-VEGF antibody were measured by enzyme-linked immunosorbent assay (ELISA). Microvessel density (MVD) of tumors was detected by immunohistochemistry 14 days after the inoculation of tumor cells.RESULTS:Tumor weight of T7-VEGF vaccine group,T7 group, and NS group were (0.543+/-0.259)g, (0.982+/-0.359)g, (1.169+/-0.460)g, respectively. Tumor weight of T7-VEGF vaccine group was significantly lower than that of NS group (P<0.01). Serum anti-VEGF antibody level in T7-VEGF vaccine group was 1:1,000. MVD was significantly lower in T7-VEGF vaccine group than in NS group (8.5+/-0.8 vs 18.5+/-1.6, P<0.05). MVD in T7 group was 16.4+/-1.3.CONCLUSION:Recombinant T7 phage vaccine expressing xenogenic VEGF can break immunologic tolerance against self-VEGF and inhibit the growth of Lewis lung cancer cells.

A bFGF Antagonist Peptide with Anti-angiogenesis Properties in Non-small Cell Lung Cancer Cells

Inhibition of Proliferation of Non-small Cell Lung Cancer Cells by a Bfgf Antagonist Peptide

Isolation of a novel basic FGF-binding peptide with potent antiangiogenetic activity.

Anti-Proliferation Effect of a Short Peptide on Bfgf-Induced Human Gastric Cancer Cells

A Novel Bfgf Antagonist Peptide Inhibits Breast Cancer Cell Growth.

Expression and Purification of FGFR1-Fc Fusion Protein and Its Effects on Human Lung Squamous Carcinoma

P7 Peptides Targeting Bfgf Sensitize Colorectal Cancer Cells to CPT-11.

Mechanism of Bfgf-Binding Peptide Reversing Adriamycin Resistance in Human Gastric Cancer Cells

Effects of a Synthetic Bfgf Antagonist Peptide on the Proteome of 3T3 Cells Stimulated with Bfgf

A Novel Fgfr1-Binding Peptide Exhibits Anti-Tumor Effect On Lung Cancer By Inhibiting Proliferation And Angiogenesis

Identification of a novel peptide that blocks basic fibroblast growth factor-mediated cell proliferation.

The FGF2-binding Peptide P7 Inhibits Melanoma Growth in Vitro and in Vivo

P7 Peptides Suppress the Proliferation of K562 Cells Induced by Basic Fibroblast Growth Factor

A novel FGF2 antagonist peptide P8 with potent antiproliferation activity

An FGF8b-mimicking Peptide with Potent Antiangiogenic Activity.

[Mechanism of Inhibitory Effect of P7 on 3T3 Cell Proliferation Induced by Basic Fibroblast Growth Factor].

FP3: a Novel VEGF Blocker with Antiangiogenic Effects in Vitro and Antitumour Effects in Vivo

A Cyclic Peptide Epitope of an Under-Explored VEGF-B Loop 1 Demonstrated In Vivo Anti-Angiogenic and Anti-Tumor Activities

[Antitumor Effect of Recombinant T7 Phage Vaccine Expressing Xenogenic Vascular Endothelial Growth Factor on Lewis Lung Cancer in Mice].

Gekko-sulfated Glycopeptide Inhibits Tumor Angiogenesis by Targeting Basic Fibroblast Growth Factor*

Identification of a Novel Afgf-Binding Peptide with Anti-Tumor Effect on Breast Cancer from Phage Display Library